TIDMFARN
Faron Pharmaceuticals Oy
03 November 2021
Faron Pharmaceuticals Ltd.
("Faron")
Cellular and Molecular Life Sciences Publishes Research on
Inhibition of Vascular Adhesion Protein-1
Enabling the Expansion of Hematopoietic Stem Cells
Company announcement, November 3, 2021
TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. ( AIM:
FARN, First North: FARON ), a clinical stage biopharmaceutical
company focused on building the future of immunotherapy by
harnessing the power of the immune system to tackle cancer and
inflammation, today announces that the multidisciplinary journal
Cellular and Molecular Life Sciences recently published research
showing the inhibition of Vascular Adhesion Protein -- 1 (VAP-1)
potentially supports the expansion of human hematopoietic stem
cells (HSC). The full manuscript titled, "Vascular adhesion
protein-1 defines a unique subpopulation of human hematopoietic
stem cells and regulates their proliferation," can be accessed
online at:
https://link.springer.com/article/10.1007%2Fs00018-021-03977-6
.
The published research aligns with Faron's pre-clinical findings
through its ongoing Haematokine program (expansion of hematopoietic
stem cells by regulating enzymatic activity of VAP-1). The study
demonstrates that an investigational AOC3 inhibitor that targets
VAP-1 and blocks its enzymatic activity has the potential to
benefit a variety of conditions where an expansion of hematopoietic
stem cells is needed. This includes hematopoietic stem cell
transplantation, where approximately 25% of transplants fail due to
poor expansion of transplanted cells.
"Our research shows for the first time that Vascular Adhesion
Protein -- 1 serves as a check point-like inhibitor, restricting
the expansion of hematopoietic stem cells," said Sirpa Jalkanen,
Academician and Professor of Immunology, University of Turku.
"Similar to what we have seen with immune checkpoint inhibitors, we
believe that inhibiting the enzymatic activity of Vascular Adhesion
Protein -- 1 enables the expansion of hematopoietic stem cells,
which are essential to the formation of new cells within blood.
This approach could have broad applicability in the fields of
regenerative medicine and the treatment of haematological
malignancies."
For more information please contact:
Media Contact
Faron Pharmaceuticals
Eric Van Zanten
Head of Communications
eric.vanzanten@faron.com
Investor.relations@faron.com
Phone: +1 (610) 529-6219
Investor Contact
Stern Investor Relations
Julie Seidel
julie.seidel@sternir.com
Phone: +1 (212) 362-1200
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
faron@consilium-comms.com
Phone: +44 (0)20 3709 5700
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a clinical stage
biopharmaceutical company developing novel treatments for medical
conditions with significant unmet needs caused by dysfunction of
our immune system. The Company currently has a pipeline based on
the receptors involved in regulation of immune response in
oncology, organ damage and bone marrow regeneration. Bexmarilimab,
a novel anti-Clever-1 humanized antibody, is its investigative
precision immunotherapy with the potential to provide permanent
immune stimulation for difficult-to-treat cancers through targeting
myeloid function. Currently in Phase I/II clinical development as a
potential therapy for patients with untreatable solid tumors,
bexmarilimab has potential as a single-agent therapy or in
combination with other standard treatments including immune
checkpoint molecules. Traumakine is an investigational intravenous
(IV) interferon beta-1a therapy for the treatment of acute
respiratory distress syndrome (ARDS) and other ischemic or
hyperinflammatory conditions. Traumakine is currently being
evaluated in global trials as a potential treatment for
hospitalized patients with COVID-19 and with the 59th Medical Wing
of the US Air Force and the US Department of Defense for the
prevention of multiple organ dysfunction syndrome (MODS) after
ischemia-reperfusion injury caused by a major trauma. Faron is
based in Turku, Finland. Further information is available at
www.faron.com .
Forward Looking Statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identified by their use of terms and phrases such as "believe",
"could", "should", "expect", "hope", "seek", "envisage",
"estimate", "intend", "may", "plan", "potentially", "will" or the
negative of those, variations or comparable expressions, including
references to assumptions. These forward-looking statements are not
based on historical facts but rather on the Directors' current
expectations and assumptions regarding the Company's future growth,
results of operations, performance, future capital and other
expenditures (including the amount, nature and sources of funding
thereof), competitive advantages, business prospects and
opportunities. Such forward looking statements reflect the
Directors' current beliefs and assumptions and are based on
information currently available to the Directors.
A number of factors could cause actual results to differ
materially from the results and expectations discussed in the
forward-looking statements, many of which are beyond the control of
the Company. In particular, the early data from initial patients in
the MATINS trial may not be replicated in larger patient numbers
and the outcome of clinical trials may not be favourable or
clinical trials over and above those currently planned may be
required before the Company is able to apply for marketing approval
for a product. In addition, other factors which could cause actual
results to differ materially include the ability of the Company to
successfully licence its programmes within the anticipated
timeframe or at all, risks associated with vulnerability to general
economic and business conditions, competition, environmental and
other regulatory changes, actions by governmental authorities, the
availability of capital markets or other sources of funding,
reliance on key personnel, uninsured and underinsured losses and
other factors. Although any forward-looking statements contained in
this announcement are based upon what the Directors believe to be
reasonable assumptions, the Company cannot assure investors that
actual results will be consistent with such forward looking
statements. Accordingly, readers are cautioned not to place undue
reliance on forward looking statements. Subject to any continuing
obligations under applicable law or any relevant AIM Rule
requirements, in providing this information the Company does not
undertake any obligation to publicly update or revise any of the
forward-looking statements or to advise of any change in events,
conditions or circumstances on which any such statement is
based.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFEELFLVIIL
(END) Dow Jones Newswires
November 03, 2021 11:54 ET (15:54 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2023 to Apr 2024